Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression

Experimental and Molecular Pathology

Volumn 94, Issue 2, 2013, Pages 360-365

  Kim, Yeong Hwa ^a   Kim, Jang Hee ^a   Choi, Yong Won ^a   Lim, Seo Kyung ^a   Yim, Hyunee ^a   Kang, Seok Yun ^a   Chung, Yong Sik ^a   Lee, Ga Young ^a   Park, Tae Jun ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Breast cancer; ErbB2; Gankyrin; P53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GANKYRIN; LENTIVIRUS VECTOR; PROGESTERONE RECEPTOR; PROTEASOME; SHORT HAIRPIN RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MIDDLE AGED; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 84874471740     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.12.002     Document Type: Article

References (28)

1. Chernova O.B., et al. The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Trends in Biochemical Sciences 1995, 20:431-434.
2. Couturier J., et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Modern Pathology 2000, 13:1238-1243.
3. Dawson S., et al. Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26S proteasome. Journal of Biological Chemistry 2002, 277:10893-10902.
4. Fourquet A., et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. International Journal of Radiation Oncology, Biology, and Physics 1989, 17:719-725.
5. Fu J., et al. p28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 2011, 53:181-192.
6. Goldstein S.N. Controversies in pathology in early-stage breast cancer. Seminars in Radiation Oncology 2011, 21:20-25.
7. Higashitsuji H., et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nature Medicine 2000, 6:96-99.
8. Higashitsuji H., et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005, 8:75-87.
9. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews. Cancer 2005, 5:341-354.
10. Iakovlev V.V., et al. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Clinical Cancer Research 2008, 14:4446-4454.
11. Kallioniemi O.P., et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:5321-5325.
12. Krzywda S., et al. The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19S proteasomal ATPase regulator, and the tumor suppressors Rb and p53. Journal of Biological Chemistry 2004, 279:1541-1545.
13. Li J., Tsai M.D. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry 2002, 41:3977-3983.
14. Li J., et al. Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Research 2011, 31:2683-2692.
15. Liao N., et al. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathology Research and Practice 2011, 207:1-7.
16. Manjasetty B.A., et al. X-ray structure of human gankyrin, the product of a gene linked to hepatocellular carcinoma. Proteins 2004, 55:214-217.
17. Meng Y., et al. Gankyrin promotes the proliferation of human pancreatic cancer. Cancer Letters 2010, 297:9-17.
18. Ortiz C.M., et al. Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. International Journal of Cancer 2008, 122:325-332.
19. Park T.J., et al. Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma. Molecular Carcinogenesis 2001, 30:138-150.
20. Pauletti G., et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996, 13:63-72.
21. Pavelic Z.P., et al. c-Myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Research 1992, 52:2597-2602.
22. Qiu W., et al. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells. Oncogene 2008, 27:4034-4043.
23. Ryoo M.C., et al. Prognostic factors for recurrence and cosmesis in 393 patients after radiation therapy for early mammary carcinoma. Radiology 1989, 172:555-559.
24. Schnitt S.J., et al. Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy. Cancer 1987, 59:675-681.
25. Tang S., et al. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biology & Therapy 2010, 9:88-95.
26. Tavassoli M., et al. Loss of wild-type p53 and C-erbb2 amplification correlates with high-grade breast carcinomas. International Journal of Oncology 1995, 6:181-186.
27. Thakur P.K., Hassan I. Discovering a potent small molecule inhibitor for gankyrin using de novo drug design approach. International Journal of Computational Biology and Drug Design 2011, 4:373-386.
28. Yuan C., et al. Solution structure of the human oncogenic protein gankyrin containing seven ankyrin repeats and analysis of its structure-function relationship. Biochemistry 2004, 43:12152-12161.